结论：奥美沙坦与微量蛋白尿延缓出现有关，尽管基于现行标准，两组患者的血压控制情况均较好。
CONCLUSIONS: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.
对糖尿病组患者进行眼底、尿微量白蛋白、尿肌酐和颈动脉、股动脉、髂总动脉内中膜厚度（IMT）检查。
Eye fundus, urine microalbumin, urine creatinine and intima-media thickness(IMT) of carotid artery, femoral artery and common iliac artery were observed in diabetic group.
微量白蛋白尿组发生联合终点事件的机率较正常UACR组高43%。
Patients with microalbuminuria were 43 percent more likely to reach the combined end point than those with normal UACR.
结果高血压和糖尿病组病人中尿微量白蛋白的变化和肾损伤的程度呈正相关性。
Results Positive correlation is expressed between the level of kidney trauma and the variation of microdose albumin in the high blood pressure group patients and diabetes group patients.
结果：治疗组血流变学、24小时尿微量蛋白定量疗效明显优于对照组。
Results:The groups of treatment on effect were obervious better than contrast groups in bloodflow change and mivroprotein in 24 hours urine.
巨量白蛋白尿的患者组，其肾病进展的危险因素与微量白蛋白尿组相似，其进展的患者肾小球滤过率较低（GFRs）且诊断有心血管疾病或心力衰竭。
The macroalbuminuria group had risk factors similar to the microalbuminuria group, and had lower glomerular filtration rates (GFRs) and a diagnosis of cardiovascular disease or heart failure.
但之后统计的数据均提示，奥美沙坦组出现微量白蛋白尿的患者少于安慰剂组。
For the remainder of the study, fewer patients in the olmesartan group experienced microalbuminuria, compared with patients in the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
应用推荐